Back to Search Start Over

Cerebrovascular Events in Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation: A Pooled Patient-Level Study.

Authors :
van Nieuwkerk AC
Aarts HM
Hemelrijk KI
Urbano Carrillo C
Tchétché D
de Brito FS Jr
Barbanti M
Kornowski R
Latib A
D'Onofrio A
Ribichini F
García-Blas S
Dumonteil N
Abizaid A
Sartori S
D'Errigo P
Tarantini G
Lunardi M
Orvin K
Pagnesi M
Navarro F
Dangas G
Mehran R
Delewi R
Source :
Journal of the American Heart Association [J Am Heart Assoc] 2024 Sep 03; Vol. 13 (17), pp. e032901. Date of Electronic Publication: 2024 Aug 27.
Publication Year :
2024

Abstract

Background: Cerebrovascular events remain one of the most devastating complications of transcatheter aortic valve implantation (TAVI). Data from real-world contemporary cohorts on longitudinal trends and outcomes remain limited. The aim of this study was to assess incidence, temporal trends, predictors, and outcomes of cerebrovascular events following transfemoral TAVI.<br />Methods and Results: The CENTER2 (Cerebrovascular Events in Patients Undergoing Transcatheter Aortic Valve Implantation With Balloon-Expandable Valves Versus Self-Expandable Valves 2) study includes patients undergoing TAVI between 2007 and 2022. The database contains pooled patient-level data from 10 clinical studies. A total of 24 305 patients underwent transfemoral TAVI (mean age 81.5±6.7 years, 56% women, median Society of Thoracic Surgeon Predicted Risk of Mortality 4.9% [3.1%-8.5%]). Of these patients, 2.2% (n=534) experienced stroke in the first 30 days after TAVI, and 40 (0.4%) had a transient ischemic attack. Stroke rates remained stable during the treatment period (2007-2010: 2.1%, 2011-2014: 2.5%, 2015-2018: 2.1%, 2019-2022: 2.1%; P <subscript>trend</subscript> =0.28). Moreover, 30-day cerebrovascular event rates were similar across Society of Thoracic Surgeon Predicted Risk of Mortality risk categories: 2.1% in low-risk, 2.6% in intermediate-risk, and 2.5% in high-risk patients ( P =0.21). Mortality was higher in patients with 30-day stroke than without at 30 days (20.3% versus 4.7%; odds ratio, 5.1 [95% CI, 4.1-6.5]; P <0.001) and at 1 year (44.1% versus 15.0%; hazard ratio, 3.5 [95% CI, 3.0-4.2]; P <0.001). One-year mortality rates for stroke did not decline over time (2007-2010: 46.9%, 2011-2014: 46.0%, 2015-2018: 43.0%, 2019-2022: 39.1%; P <subscript>trend</subscript> =0.32). At 1 year, 7.0% of patients undergoing TAVI had a stroke.<br />Conclusions: In 24 305 patients who underwent transfemoral TAVI, 30-day cerebrovascular event incidence remained ≈ 2.2% between 2007 and 2022. Thirty-day stroke rates were similar throughout Society of Thoracic Surgeon Predicted Risk of Mortality risk categories. Mortality rates after stroke remain high.<br />Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03588247.

Details

Language :
English
ISSN :
2047-9980
Volume :
13
Issue :
17
Database :
MEDLINE
Journal :
Journal of the American Heart Association
Publication Type :
Academic Journal
Accession number :
39190595
Full Text :
https://doi.org/10.1161/JAHA.123.032901